Regeneron posted its Eylea updates as the company reported ... cholesterol med Praluent, suffered a 19% sales decline to $57 million in the U.S. The company also shares sales on the immunology ...

Regeneron’s shares have lost 14.1% year to date compared with the industry’s decline of 4.7%. Image Source: Zacks Investment Research Eylea’s sales in the United States plunged 39% year over year to ...

Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big ...

Starting in 2025, the Eylea franchise as a whole began to decline due to ... We assign Regeneron a Medium Morningstar Uncertainty Rating, as its future sales are well diversified with several ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. The initial uptake of Eylea HD has been strong as Eylea patients transition to the higher dose. Sales of Eylea ...

Regeneron Pharmaceuticals ... affordability challenges. Still, EYLEA HD posted a 54% increase in U.S. sales to $307 million, partially offsetting the decline. Dupixent remains a growth driver ...

Sales of oncology drug, Libtayo, also missed estimates. Shares are trading down in response to lower-than-expected results. Regeneron’s shares have lost 14.1% year to date compared with the industry’s ...